International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 doi: 10.5281/zenodo.10152823
Original Article
Correlation of Cord Blood Bilirubin Values with Neonatal Hyperbilirubinemia in Healthy Term Newborns in a Setting of Abo Incompatibility
 ,
 ,
 ,
 ,
Published
Nov. 17, 2023
Abstract

Background: Newborns with hyperbilirubinemia are at greater risk of kernicterus. Neonatal screening for hyperbilirubinemia helps to prevent kernicterus.

Aim: To find the correlation between cord blood bilirubin at birth and serum bilirubin at 72 hours of a neonate.

Method: Cord blood was drawn from 353 neonates, shortly after birth. The sample was then tested for both blood grouping and typing and total bilirubin levels. After 72 hours of birth, a second serum bilirubin test was carried out, and data was analysed to determine the correlation.

Results: In our study, neonates with significant hyperbilirubinemia (>15 mg/dl) around 72 hours of life had significantly elevated levels of cord blood bilirubin (≥2.5mg/dl. Cord Blood Bilirubin < 2.5 mg/dl can help to identify those newborns who are unlikely to require further evaluation and intervention.

Conclusion: Babies with Cord Blood Bilirubin level ≥ 2.5 mg/dl should be followed more frequently to reduce morbidity due to Neonatal hyperbilirubinemia.

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
785 Views
47 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved